MedTrace Logo

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

NCT06621563 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 780

Last updated 2025-04-09

No results posted yet for this study

Summary

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.

Conditions

Interventions

DRUG

HS-20117 combined HS-20093

HS-20117 + HS-20093

DRUG

HS-20117 combined Platinum-containing chemotherapy

HS-20117 + cisplatin/carboplatin + pemetrexed

DRUG

HS-20117 combined HS-20093 and 5-FU

HS-20117 + HS-20093 + 5-FU

DRUG

HS-20117+CAPEOX

CAPOEX: Oxaliplatin+Capecitabine

DRUG

HS-20117+FOLFIRI

FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU

DRUG

HS-20117+mFOLFOX6

mFOLFOX6=Oxaliplatin+Leucovorin Calcium+5-FU

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-14
Primary Completion
2026-03-30
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06621563 on ClinicalTrials.gov